was calculated based on the afterload fibre defection that was measured with the cardiac microtissue at maximal contraction (that is, the systolic state). All contractile function analyses were performed on only the microtissues with regular contraction kinetics (normalized errors in τ 75 < 0.1).
T he myosin-binding protein C cardiac isoform (MYBPC3) is a thick-filament accessory protein of the striated muscle sarcomere A-band, and mutations in MYBPC3 are implicated in both hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) 1 . The molecular mechanisms by which MYBPC3 mutations lead to the contractile deficits for DCM phenotypes remain elusive, while increasing numbers of reports from mouse models indicate that stress plays a role in the initiation and progression of the physiopathology process associated with MYBPC3 mutations 2 . Human induced pluripotent stem cell (hiPSC) technology has provided previously unanticipated possibilities to model human heart diseases in cell culture, but these models have tended to simplify the diseases as monogenic, hereditary forms of diseases, which neglects the diversity in disease phenotypes resulting from genetic-environmental interactions. Mechanical cues such as afterload play a particularly important role in the normal function of the heart and the pathogenesis of diseases such as cardiomyopathy. Incorporating environmental stresses such as mechanical cues into engineered hiPSC-based tissue models would provide the opportunity to model disease phenotypes with high precision.
Three-dimensional (3D) engineered cardiac tissue models that mimic native tissue structures have been developed using a variety of methodologies and materials that share a common process of hiPSC-derived cardiomyocyte (hiPSC-CM) encapsulation into external hydrogels 3, 4 . To promote hiPSC-CM alignment and the formation of physiologically relevant tissue structures, the 3D cardiac tissues are anchored between two flexible cantilevers, which also serve as a force sensor [5] [6] [7] . However, this measurement is compromised by the complex mechanical and biochemical contribution of extracellular matrix (ECM) hydrogels such as collagen, which alter tissue formation, mechanical properties 8 and cellular contractile forces 8 . Therefore, self-assembled cardiac tissues relying on endogenous secretion of cardiac-specific ECMs are being explored for more consistent tissue self-assembly and remodelling 9 .
The biophysical microenvironment plays a critical role in cardiac pathophysiology. For example, the afterload against which the heart contracts directly relates to the mechanical stretch on cardiomyocytes and plays an important role in the pathogenesis of DCM 10 . Contraction force-a key component of cardiac function-is continuously regulated by the surrounding environment 11 . The contraction force of hiPSC-CMs has been deemed as one of the essential parameters for the evaluation of normal mature cardiac function, response to pharmacological interventions and indication of disease phenotypes [12] [13] [14] . The force sensors used in the cardiac tissue models not only report the contraction forces generated by hiPSC-CMs, but also naturally become the external mechanical load that regulates the cardiac tissue remodelling and function. In traction force microscopy, variation of substrate stiffness altered the myofibril organization of two-dimensional micropatterned hiPSC-CMs, demonstrating that substrata with optimal stiffness improved The integration of in vitro cardiac tissue models, human induced pluripotent stem cells (hiPSCs) and genome-editing tools allows for the enhanced interrogation of physiological phenotypes and recapitulation of disease pathologies. Here, using a cardiac tissue model consisting of filamentous three-dimensional matrices populated with cardiomyocytes derived from healthy wild-type (WT) hiPSCs (WT hiPSC-CMs) or isogenic hiPSCs deficient in the sarcomere protein cardiac myosin-binding protein C (MYBPC3 -/-hiPSC-CMs), we show that the WT microtissues adapted to the mechanical environment with increased contraction force commensurate to matrix stiffness, whereas the MYBPC3 -/microtissues exhibited impaired force development kinetics regardless of matrix stiffness and deficient contraction force only when grown on matrices with high fibre stiffness. Under mechanical overload, the MYBPC3 -/microtissues had a higher degree of calcium transient abnormalities, and exhibited an accelerated decay of calcium dynamics as well as calcium desensitization, which accelerated when contracting against stiffer fibres. Our findings suggest that MYBPC3 deficiency and the presence of environmental stresses synergistically lead to contractile deficits in cardiac tissues.
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NaTUre BiOMediCal eNgiNeeriNg the contractile activity of hiPSC-CMs 15 . In 3D cardiac tissue models, flexible cantilevers used to anchor cardiac tissues also presented a rigid external structure to mimic in vitro cardiac tissue afterload 16 . Increasing the mechanical load to hiPSC-CMs from patient-specific and genome-engineered hiPSCs facilitated better modelling of DCM associated with TTN gene mutations 17 . In contrast, optimal mechanical load was critical for the 3D maintenance and maturation of hiPSC-CMs with highly organized sarcomeres, as well as increased adherens and gap junction formation 18 .
To address the hypothesis that tissue mechanical resistance to contraction can regulate cardiomyocyte sensitivity to the loss of MYBPC3, in the absence of complex interactions between cells and natural ECM-derived gels, we created a cardiac tissue model that employed highly ordered 3D fibres. The structure and mechanical properties of these fibres promoted cardiac tissue self-assembly and dynamic remodelling. Using two-photon polymerization (TPP), we created different filamentous matrices by fabricating precisely defined, ultra-high-aspect-ratio synthetic parallel fibres with different fibre diameters (that is, 5 and 10 µ m). Although these fibres have a constant elastic modulus, thicker fibres have a higher mechanical resistance to cellular contraction than thinner fibres. We populated wild-type (WT) hiPSC-CMs or isogenic MYBPC3 -/-hiPSC-CMs that completely lack expression of the sarcomere protein MYBPC3. WT cardiac microtissues adapted their contraction velocity and contraction force to the alternations of mechanical load. In contrast, MYBPC3 -/cardiac microtissues exhibited impaired force relaxation kinetics, but only exhibited defects in the total systolic contractile force, compared with WT microtissues, when challenged with stiffer fibres. These results suggest that the cardiac tissue's mechanical microenvironment facilitated the modelling of contractile deficits associated with the absence of MYBPC3 protein. Incorporation of appropriate mechanical resistance to cardiac contractility will be an important aspect of future efforts to model human heart disease in vitro.
Results
Matrix fabrication and cardiac microtissue self-assembly and remodelling. Filamentous matrices were fabricated using TPP to produce scaffolds with highly defined micro-and nanoscale features (Supplementary Fig. 1a and Supplementary Video 1) [19] [20] [21] . Based on previous studies, we concluded that the filamentous matrices, consisting of parallel 500-µ m-long fibres in the y axis direction, 50 µ m fibre spacing in the x axis direction and 30 µ m layer spacing in the z axis direction, could robustly generate 3D condensed cardiac microtissues 22 ( Supplementary Fig. 1b ). In this study, we fabricated multiple matrices within one pair of glass coverslips by separating cohorts of fibre matrices with 2 mm spacing along the x axis ( Supplementary Fig. 1b ). This design not only increased the throughput, but also made the fibre deflection easier to measure for contraction force calculations. Scanning electron microscopy confirmed a matrix with parallel fibres, and the ability to control fibre diameter (for example, 5 versus 10 µ m) ( Supplementary Fig. 1c ).
We seeded hiPSC-CMs onto filamentous matrices without any additional cell-encapsulating ECM gel. The generation of 3D cardiac microtissues required a relatively purified hiPSC-CM population and consistent cell-handling procedures ( Supplementary  Fig. 2a ). Purification procedures 23, 24 can routinely produce highly purified cardiomyocyte populations (cTnT + cells: > 95%). However, 3D engineered cardiac microtissues require a stromal cell or fibroblast population to enhance the mechanical integrity and connectivity of tissues 9, 25, 26 . Instead of 6 days of treatment with lactate purification media, we treated our cells for only 4 days, which resulted in a mixed hiPSC-CM population (TNNT2 + cells: ~80%; Supplementary Fig. 2b,c) .
The hiPSC-CMs seeded on the filamentous matrices self-assembled into 3D cardiac microtissues (z axis thickness: ~60 µ m; Supplementary Fig. 3a,b ) and maintained a stable beat rate after 5 d of culturing. The cardiac microtissues continuously and progressively remodelled in response to the passive mechanical load of the fibres and active tissue contraction. The beat rate, contraction velocity, contraction force and width of the individual cardiac microtissues were measured every 5 d to track the tissue remodelling associated with the change of functional readouts. Since the individual fibres were fixed onto the glass coverslips at both ends, the contracting cardiac microtissues were only able to deform the fibres in the x direction, but not in the y direction (Supplementary Video 2). This mechanical constraint resulted in anisotropic contraction, with higher contraction along the x axis compared with the y axis, as defined by contraction heat maps ( Fig. 1a ). We calculated the ratio of the contraction velocity in the x and y directions, and found a significant increase in the ratio from day 5 to day 20 ( Fig. 1b ). We also observed that the microtissues condensed in the direction of the y axis, but maintained the integrity along the x axis, resulting in a significant decrease in the tissue cross-section areas (z-y direction) from day 5 to days 10-20 ( Fig. 1c ). These data suggest that the change in tissue shape occurred simultaneously with the orientation of the contraction directions, thus anisotropic contraction and anisotropic tissue shape reinforced each other during the tissue remodelling process.
Mechanical load affected cardiac microtissue contractile functions.
To test the hypothesis that mechanical overloading influences cardiac tissue functions, we created matrices with different fibre diameters. By changing the fibre diameter, we could change the fibre bending stiffness to modulate the mechanical load to the cardiac microtissues assembled around the fibres. Based on atomic force microscopy (AFM) calibration of individual fibres, we calculated the elastic modulus of the material as 183.9 ± 11.7 MPa, which refers to the linear ratio of force load and deformation of the fibre. Although the elastic modulus was the same for both fibres, the fibre bending stiffness against which cells had to contract was proportional to the square of the fibre diameter, thus 5 µ m fibres were much easier to bend compared with 10 µ m fibres. We did not observe a significant difference in the beat rate of the cardiac microtissues between 5 and 10 µ m matrices, but the beat rate slightly increased from days 5-10 to days 15-20 ( Fig. 1d ). Since 5 µ m fibres are easier to bend, we found a higher maximal contraction velocity for cardiac microtissues assembled on the 5 µ m matrices compared with the 10 µ m matrices ( Fig. 1e ). These data suggest that modulating the mechanical load of the tissue microenvironment by changing the fibre bending stiffness altered the contractile functions of the cardiac microtissues.
We used the deflection of individual fibres to calculate the force of contraction. By assuming that all of the forces throughout the tissue cross-section were evenly distributed and parallel ( Supplementary Fig. 4a ), we calculated the point force exerted on an individual fibre based on the fibre deflection and force position (where the maximal deflection locates) measured in a series of recorded images ( Supplementary Fig. 4b ). Using this point force, we could also calculate the total force generated by the cardiac microtissues. Through theoretical calculations, we found that the force measured by a 10 µ m fibre was approximately tenfold higher than the force measured by a 5 µ m fibre with the same fibre deflection and force position ( Supplementary Fig. 4d,e ). Therefore, by artificially applying the forces at the centre region of each fibre with 1 µ N to a 5 µ m fibre and 10 µ N to a 10 µ m fibre, we could determine the stress generated on the fibres through COMSOL numerical simulation. High stress occurred at the centre region of the fibre, where the force was applied, and also at the two ends of the fibre, where the fibre was fixed at both sides of the glass coverslips ( Supplementary  Fig. 4c and Supplementary Video 3). The motion close to the glass substrates in the heat maps of mean y velocity only resulted from fibre movement during tissue contractions, since no tissue had grown at these locations. Scale bar, 100 µ m. b,c, The progressive tissue remodelling from day 5 to days 10-20 manifested as an increase in the ratio of mean contraction between the x and y axis directions (b) (Bonferroni's multiple comparison analysis of variance test, *P = 0.0086 for 5 µ m matrices; *P = 0.0004 for 10 µ m matrices) and a decrease in the tissue cross-section (z-y direction) (c) (Bonferroni's multiple comparison analysis of variance test, *P = 0.0001 for 5 µ m matrices; *P = 0.0135 for 10 µ m matrices). d, The beat rate of cardiac microtissues slightly increased from days 5-10 to days 15-20 (two-tailed Student's t-test, *P = 0.005 for 5 µ m matrices; *P = 0.004 for 10 µ m matrices). e, Although we found no significant effect of the tissue mechanical environment on beat rate (d), the maximum contraction velocity was much higher for the cardiac microtissues assembled on 5 µ m matrices than those on 10 µ m matrices (two-tailed Student's t-test, *P = 0.0035 for day 5; *P = 0.0052 for day 10; *P = 0.000131 for day 15; *P = 0.0000415 for day 20). In b-e, n = 6 and box plots show the minimum, maximum, median, and 25th and 75th percentiles.
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Cardiac preload is defined as end-diastolic myocardial wall tension. In this study, we refer to preload as the passive tension exerted by the fibres at two edges of the matrix to the diastolic cardiac microtissue at the resting state. The load opposing shortening of the ventricular muscles is termed cardiac afterload. Here, the cardiac tissue afterload is defined as the fibre tension against the systolic cardiac microtissue at the maximal contraction ( Fig. 2a ). The afterload considerably increases when the cardiac microtissues contract against the stiffer fibres. Based on the fibre deflection-force relationship discussed above, we calculated the static forces (diastole) and contraction forces (systole) for the cardiac microtissues assembled on both 5 and 10 µ m matrices, and found that cardiac microtissues produced higher forces when grown on the matrices with stiffer fibres. We found that the static forces increased significantly from day 5 to day 20 for the cardiac microtissues assembled on both 5 and 10 µ m matrices (Fig. 2b,c) , whereas the contraction forces increased significantly only when the microtissues grew on the 10 µ m matrices, and not on the 5 µ m matrices ( Fig. 2d,e ). Selfassembled WT hiPSC-CMs on the 10 µ m filamentous matrices adapted to the high stiffness and increased the contraction force through mechanical overloading.
Isogenic MYBPC3 -/cardiac microtissues exhibit force deficits without structural disarray.
To test the hypothesis that mechanical resistance synergizes with genetics to cause contraction deficits, we harnessed transcription activator-like effector nucleases (TALENs)-assisted gene-editing to create an isogenic human homozygous MYBPC3 null cardiac microtissue model. MYBPC3 is a thick-filament-associated protein that is thought to play a principally structural role in the stabilization of sarcomere sliding during contraction 27, 28 ( Supplementary Fig. 5a ). Fluorescence images of WT hiPSC-CMs showed the MYBPC3 protein aligned with the sarcomeric α -actinin (ACTN2) protein, indicating the structural relationship of A-bands and Z-discs ( Supplementary  Fig. 5b ). Furthermore, this protein binds to thin and thick filaments, thereby regulating the probability of cross-bridge interactions, which in turn controls the rate of force development and relaxation in cardiac muscles 29 .
To test the hypothesis that environmental conditions could modulate the contraction deficits caused by loss-of-function mutations, we focused this initial study on a severe loss of function caused by complete, homozygous knockout of MYBPC3. The isogenic homozygous MYBPC3 -/-hiPSC cell line was developed using TALENbased genome editing ( Supplementary Fig. 5c ). hiPSC-CMs derived from MYBPC3 -/-hiPSC parent cells showed a complete loss of MYBPC3 messenger RNA and protein ( Supplementary Fig. 5e ,f). MYBPC3 -/-hiPSC-CMs formed the 3D anisotropic cardiac microtissues on both 5 and 10 µ m filamentous matrices (Supplementary Video 4), so we could determine how mechanical overload affected the contractile behaviours in MYBPC3 -/cardiac microtissues. There was no significant difference in the static forces between WT and MYBPC3 -/cardiac microtissues on both 5 and 10 µ m matrices ( Fig. 3a,b ), which suggested that the absence of MYBPC3 had no effect on cardiac preload. Furthermore, we did not observe a difference in the contraction forces between MYBPC3 -/and WT cardiac microtissues on 5 μ m fibres. However, we observed a marked Articles NaTUre BiOMediCal eNgiNeeriNg inhibition in contractile force development in MYBPC3 -/cardiac microtissues compared with WT microtissues on 10 μ m fibre matrices ( Fig. 3c,d ). We also found that the MYBPC3 -/cardiac microtissues showed higher contraction velocity compared with the WT microtissues, and this velocity difference was exaggerated on 10 µ m matrices ( Fig. 3e ,f). Independent of either tissue type, the magnitude of force was greater on 10 µ m matrices and the contraction velocities were significantly higher on 5 µ m matrices. These results suggest that modulating the mechanical load against which engineered cardiac microtissues contract facilitates the manifestation of contractile deficits due to the absence of the MYBPC3 protein. To rule out any effects of contraction abnormalities on these results, we only assessed the force of systolic contraction in microtissues that had regular beating behaviours (defined as s.d./mean of the beating relaxation decay time < 0.1).
Since we found substantial reduction of the contraction forces of MYBPC3 -/cardiac microtissues on 10 µ m matrices, we subsequently evaluated the structural characteristics between WT and MYBPC3 -/cardiac microtissues on 5 and 10 µ m matrices at day 20 (Fig. 4a,c) . Surprisingly, we found no significant differences in tissue cross-section areas (Fig. 4b ), sarcomere organization ( Fig. 4d ,e) or connexin 43 expression ( Supplementary Fig. 6 ) for either of the two genotypes or fibre matrix types. These results suggest that the absence of MYBPC3 protein does not induce gross tissue shape remodelling or sarcomere disarray at the in vitro tissue level within 20 d culture, but does play an important role in force development responding to the external mechanical overload.
Isogenic MYBPC3 -/cardiac microtissues exhibit abnormalities in force and calcium dynamics. As structural deficiencies were not . e,f, MYBPC3 -/cardiac microtissues showed a higher maximal contraction velocity for the cardiac microtissues assembled on both 5 µ m (e) (two-tailed Student's t-test, *P = 0.0366 for day 20) and 10 µ m (f) (two-tailed Student's t-test, *P = 0.0388 for day 15; *P = 0.0475 for day 20) matrices compared with WT cardiac microtissues. At each time point, the magnitudes of the static and contraction forces were significantly higher for WT and MYBPC3 -/cardiac microtissues grown on 10 µ m matrices, and the contraction velocities were significantly higher for the microtissues grown on 5 µ m matrices. In all panels, n = 6 and box plots show the minimum, maximum, median, and 25th and 75th percentiles.
sufficient to explain the marked force deficits in MYBPC3 -/cardiac microtissues on stiff fibre matrices, we next investigated contractile force kinetics. Since the MYBPC3 protein is thought to regulate the force development during cardiac contraction 30 , we plotted the force kinetics curves for WT and MYBPC3 -/cardiac microtissues on 5 and 10 µ m matrices at day 20. After multiplying the force and velocity, we also plotted the power kinetics curves, and measured the area under the curve as the total energy consumed by the cardiac microtissues to complete one contraction. On both 5 and 10 µ m matrices, MYBPC3 -/cardiac microtissues developed the maximal contraction forces faster than WT microtissues (Fig. 5a,c ). Since the force magnitude was similar between WT and MYBPC3 -/cardiac microtissues on the 5 µ m matrices, a higher contraction velocity led to higher power output and more energy consumption (the area of power kinetics curve) of the MYBPC3 -/cardiac microtissues (Fig. 5b) . In contrast, MYPBC3 -/cardiac microtissues on the 10 µ m matrices developed significantly lower contraction forces and less power output, but similar energy consumption compared with the WT microtissues ( Fig. 5c,d) . The same energy consumption, but low force production from MYBPC3 -/cardiac microtissues indicates that the absence of MYBPC3 protein impaired the cardiac microtissues from contracting in an energy-efficient manner. To further analyse the force kinetics, we measured the upstroke time to peak force (τ max ), early decay time of 50% peak force (τ 50 ) and late decay time of 75% peak force (τ 75 ). We found no significant difference in the cardiac microtissues between 5 and 10 µ m fibre matrices, but MYBPC3 -/cardiac microtissues were statistically faster to reach τ max (Fig. 5e ). Compared with the WT microtissues, MYBPC3 -/microtissues exhibited no significant difference in τ 50 (Fig. 5f ), but a slower τ 75 (Fig. 5g ). This delayed force relaxation is consistent with an HCM-like phenotype 1 .
Previous studies have noted that hiPSC-CMs derived from patients with familial cardiomyopathy are more prone to electrophysiological abnormalities, such as early after-depolarizations (EADs) 31 . To determine how the abnormalities in calcium handling occurred on MYBPC3 -/cardiac microtissues under mechanical overload, we generated hiPSCs harbouring the genetically encoded Ca 2+ reporter GCaMP6f, which was inserted into the adeno-associated virus integration site 1 (AAVS1 'safe harbour' locus) on both WT and MYBPC3 -/-hiPSC lines ( Supplementary Fig. 5d ), allowing direct measurements of calcium dynamics. The fluorescence fluctuation of the GCaMP6f signal from the GCaMP6f cardiac 
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NaTUre BiOMediCal eNgiNeeriNg microtissue assembled on the filamentous matrices indicated the Ca 2+ dynamics of the cell ( Fig. 6a and Supplementary Video 5) , caused by the combination of L-type calcium channels and calciuminduced calcium release from the sarcoplasmic reticulum, downstream of the action potential 32 . We generated GCaMP6f-WT and GCaMP6f-MYBPC3 -/cardiac microtissues on both 5 and 10 µ m matrices, and recorded the calcium transient via the GCaMP6f reporter (Fig. 6b ). First, we analysed calcium dynamics in the microtissues that did not exhibit gross calcium transient abnormalities (defined by measuring the τ 75 of the calcium transient and selecting tissues with s.d./mean τ 75 < 0.1). Within this set of tissues, we found that there was no effect of MYBPC3 deficiency on the overall intensity of GCaMP6f, suggesting that the overall amount of Ca 2+ entering the cells remained the same. However, we did observe increased maximum GCaMP6f, corresponding to greater calcium intake, when both WT and MYBPC3 -/microtissues were challenged to contract against stiffer fibres (Fig. 6c ). By analysing calcium transient decay dynamics, we observed no significant difference in τ 50 (Fig. 6d ), but we did find that MYBPC3 -/cardiac microtissues on both 5 and 10 µ m fibre matrices exhibited faster τ 75 values of calcium transient compared with WT microtissues (Fig. 6e) .
Although EADs were rare events in all microtissues (Fig.  6f ), we observed a significantly increased probability of EAD events in MYBPC3 -/microtissues contracting against stiff fibres (Fig. 6g,h) . We also analysed the calcium sensitivity of GCaMP6f-WT and GCaMP6f-MYBPC3 -/cardiac microtissues on both 5 and 10 µ m matrices, and found a trend of calcium desensitization of MYBPC3 -/microtissues compared with WT microtissues ( Fig. 6i ). More importantly, the cardiac microtissues appeared to become further desensitized to extracellular calcium when contracting against the stiffer matrices. The mismatch between matrices was faster than for WT tissues, but there was no difference in the magnitude. b, MYBPC3 -/cardiac microtissues on 5 µ m matrices showed higher power output and energy consumption compared with WT microtissues. c,d, MYBPC3 -/cardiac microtissues on 10 µ m matrices showed impaired force generation (c) and lower power output (d) compared with WT microtissues. e, MYBPC3 -/cardiac microtissues were quicker to reach τ max compared with the WT microtissues (two-tailed Student's t-test, *P = 0.000633 for 5 µ m matrices; *P = 0.000104 for 10 µ m matrices). f,g, Although there was no significant difference in τ 50 (f), MYBPC3 -/cardiac microtissues had a longer τ 75 (g) (two-tailed Student's t-test, *P = 0.00315 for 5 µ m matrices; *P = 0.0194 for 10 µ m matrices). In a-d, n = 8 and all data are shown, along with curve fittings. In e-g, n = 8 and box plots show the minimum, maximum, median, and 25th and 75th percentiles. R 2 , coefficient of determination.
NaTUre BiOMediCal eNgiNeeriNg faster decay of calcium transient and slower decay of contraction force indicates the importance of the MYBPC3 protein for regulating the cardiac contractility through excitation-contraction coupling. This is consistent with data obtained in cell-free, reconstituted protein assays that implicate MYBPC3 protein as a potential 'molecular brake' controlling the rate of force development and relaxation in heart muscle 30 .
To begin to understand the mechanisms through which stiffer matrices affected the pathology of the MYBPC3 -/-hiPSC-CMs, we profiled gene expression (102 genes) for the WT and MYBPC3 -/cardiac microtissues on 10 µ m matrices (Fig. 7a ). Although we found no significant difference in either the sarcomere structural deficit (MYH6 and MYH7) or calcium handling malfunction (CALM1 and CALM3), which have been typically related to HCM, c, Cardiac microtissues growing on 10 µ m matrices had a higher peak intensity compared with those on 5 µ m matrices (two-tailed Student's t-test, *P = 0.0288 for WT; *P = 0.00152 for MYBPC3 -/-). d,e, Although there was no significant difference in τ 50 (d), GCaMP6f-MYBPC3 -/cardiac microtissues had a shortened τ 75 on both 5 and 10 µ m fibre matrices (e) (two-tailed Student's t-test, *P = 0.00104 for 5 µ m matrices; *P = 0.000162 for 10 µ m matrices). f, Representative traces for regular calcium dynamics (left) and EAD-like calcium dynamics (right) measured from GCaMP6f-MYBPC3 -/cardiac microtissues. g,h, The GCaMP6f-MYBPC3 -/cardiac microtissues showed significantly higher variations in normalized error in τ 75 (g) (two-tailed Student's t-test, *P = 0.0253 for 10 µ m matrices) and significantly higher probability of EAD behaviours when growing on 10 µ m matrices (h) (two-tailed Student's t-test, *P = 0.0178). i, Calcium desensitization was found on MYBPC3 -/cardiac microtissues compared with WT microtissues, as well as microtissues contracting against stiffer fibres. In c-e, g and h, n = 10 and box plots show the minimum, maximum, median, and 25th and 75th percentiles. In i, n = 6 and means ± s.d. are shown for all data.
NaTUre BiOMediCal eNgiNeeriNg GNAS  CALM2  CALM1  IL6ST  GNAL1  TNNT2  NKX2-5  MAPK1  MEF2A  GNAQ  CSNK1A1  HRAS  PIK3R1  PRKAR1A  HDAC3  HAND2  GATA4  EDN1  EP300  MAP2K2  HDAC2  PRKAR2B  GNAI3  CALM3  GSK3B  CREBBP  HDAC1  NRAS  PKAR2A  SOS1  PLCG1  MYH7  IGF1R  MYH6  CAMK2B  MAPK8  MAP2K3  CAMK2A  MAPK14  TBX5  PRKACA  MEF2C  PPP3CA  HAND1  GNAI2  PLCB1  AKAP5  SCN5A  ISL1  PRKCZ  TNNI3  POUSF1  RCAN1  MAP2K4  RAF1  MAP3K1  NANOG  CANA1C  IL6  MAP2K6  PRKCA  ITPR1  KRAS  MESP1  GNA11  MAPK10  AKT1  MAPK3  MAP3K7  PIK3CA  MAP2K1  PIK3R2  SLC9A1  T  CAMK2G  PLCG2  PRKCD  SRC  AGT  MAP3K5  CAMK4  ACNA1G  HDAC6  PRKCE  IGF1  PIK3CD  ADCY3  SCNN1G  SCNN1B  CABIN1  CACNA1H  CACNA1S  ELSPBP1  IL11  ITPR3  LIF  MAPK13  HDAC4  SCNN1A  SCN1A NFATC4 MAPK12 c 5 μm MYBPC3 -/- Fig. 7 | EP300-and GATA4-directed contractile deficits due to mechanical stress. a, At day 20, 102 genes were profiled for WT and MYBPC3 -/cardiac microtissues growing on 10 µ m matrices. b, Gene expression of EP300 (*P = 0.0798), CREBBP (*P = 0.022), HDAC1 (*P = 0.0331) and GATA4 (*P = 0.034) on MYBPC3 -/cardiac microtissues was significantly higher compared with WT cardiac microtissues grown on 10 µ m filamentous matrices (two-tailed Student's t-test). c, At day 20, hBNP expression as measured by enzyme-linked immunosorbent assay was found to be significantly higher on MYBPC3 -/cardiac microtissues than on WT cardiac microtissues only grown on 10 µ m matrices (n = 4; two-tailed Student's t-test, *P = 0.0478 for matrices comparison; *P = 0.0015 for WT versus MYBPC3 -/comparison on 10 µ m matrices; NS, not significant). d, Confocal images of p300 fluorescence staining on both WT and MYBPC3 -/cardiac microtissues on 5 and 10 µ m filamentous matrices. e, Quantitative fluorescence analysis of p300 expression showed that the cardiac microtissues on 10 µ m matrices had higher p300 expression than those on 5 µ m matrices, and MYBPC3 -/cardiac microtissues had higher p300 expression than WT microtissues (n = 6; two-tailed Student's t-test, *P = 0.0269 for matrices comparison; *P = 0.00504 for WT versus MYBPC3 -/comparison on 5 µ m matrices; *P = 0.0345 for WT versus MYBPC3 -/comparison on 10 µ m matrices). In b, n = 3 and means ± s.d. are shown for all data. Box plots show the minimum, maximum, median, and 25th and 75th percentiles.
NaTUre BiOMediCal eNgiNeeriNg we identified four genes (EP300, CREBBP, HDAC1 and GATA4) that were significantly upregulated in the MYBPC3 -/microtissues ( Fig. 7b ). We also found that the expression of human brain natriuretic peptide (hBNP) between WT and MYBPC3 -/cardiac microtissues only became significantly different when the cardiac microtissues grew on 10 µ m matrices, suggesting that the observed loss of contraction force is concurrent with molecular indicators of disease progression in the MYBPC3 -/microtissues (Fig. 7c ). Via confocal microscopy and quantitative fluorescence measurements, we determined that EP300 protein expression significantly increased on the cardiac microtissues grown on the 10 µ m matrices compared with those grown on 5 µ m matrices (Fig. 7d ). Furthermore, we found that EP300 protein expression in MYBPC3 -/cardiac microtissues was significantly higher than in WT microtissues on both 5 and 10 µ m matrices, suggesting that EP300 plays a key role in the synergy between genetic deficiency and mechanical overload in inducing contractile deficits (Fig. 7e ).
discussion
In this work, we combined hiPSC technology, genome-editing tools and advanced material processing to create a next-generation hiPSC-based cardiac tissue model, which recapitulated the synergism of genetic deficiencies and environmental stresses required to induce life-threatening cardiomyopathies. We innovated the conventional TPP technique to enable fabrication of high-aspect-ratio (100:1) fibres with reasonable throughput, which ensured the structural support and force sensing function used in our cardiac tissue model 33 . Such aspect ratios are impossible to achieve with standard microfabrication technology. Furthermore, unlike other methods to create filamentous matrices, such as electrospinning, self-assembly and 3D micropatterning of hydrogels, our TPP technique has unprecedented control over a wide range of matrix features deemed important in allowing immediate cell infiltration for 3D tissue formation and regulating tissue mechanical functions 22 . As well as harnessing the mechanical load of the fibre matrix as the environmental stress to the hiPSC-CMs, we used the genome editing to engineer isogenic diseased hiPSC lines to precisely control the genetic background 34, 35 , to understand the pathogenesis from a specific gene mutation and its interaction with environmental stress. Previous studies from MYBPC3 knockout mice have exhibited impaired contractile properties, with overall reduction in diastolic and systolic functions observed at the whole heart level 36, 37 . Consistent with our hiPSC model, myofilament Ca 2+ sensitivity of tension was also reduced in MYBPC3 -/mice, with a right-shifted normalized Ca 2+ tension curve relative to WT mice. Our findings that MYBPC3 -/cardiac microtissues are viable and display welldeveloped sarcomeres conflict with the previous hypothesis that MYBPC3 protein plays essential structural roles for sarcomere assembly and stability. However, our study is consistent with the MYBPC3 -/mouse model, in which the well-organized sarcomere striation patterns were observed in nearly all sections of heart tissues 36 . Our results, together with mouse models, indicate that the MYBPC3 protein is not an absolute requirement for the assembly and maintenance of organized sarcomeres and myofibrils, but serves a complimentary role in modulating cardiac contractile functions.
To examine the regulatory effects of the MYBPC3 protein on cardiac contractile function, multiple heterozygous and homozygous mouse models have been established with confounding results. One in vitro homozygous MYBPC3 -/mouse tissue model demonstrated characteristic acceleration of contraction kinetics (a hyper-contractile HCM-like disease phenotype 38 However, if pressure overload was induced by transverse aortic constriction, these mice developed left ventricular dilation and reduced contractile functions. These results suggest that mechanical stress in the form of increased afterload may be required to observe phenotypes associated with MYBPC3 loss-of-function mutations. This is consistent with the observation that systemic resistance is a major risk factor for heart failure in the setting of cardiomyopathy 10 . These indications also lean towards the clinical findings that a subset of patients with HCM associated with heterozygous MYBPC3 truncated mutations could later develop left ventricular dilation and systolic dysfunction similar to DCM, otherwise known as 'burnt out' phase HCM or end-stage HCM. However, these murine-based in vivo models make it very difficult to specifically isolate the biomechanical aetiology underlying the disease onset and process, as transverse aortic constriction or other manoeuvres that increase cardiac afterload also affect global signalling through inflammation and other processes 41 . In contrast, our hiPSC-based in vitro model eliminates the complex changes in soluble milieu related to the manoeuvres used in animal models for cardiac overload, and also allows the disease process to be modelled in genetically defined human cells.
At present, hiPSC-based MYBPC3-related disease models have only been established at single-cell or two-dimensional monolayer levels. A previous report on patient-derived hiPSC-CMs carrying a heterozygous MYBPC3 mutation (c.2373dupG) micropatterned at the single-cell level showed systolic dysfunction with lower contractile force generation compared with healthy controls 42 . Consistent with the hypothesis that MYBPC3 -/genotypes reduce contractile force, a recent study using an allelic series of isogenic MYBPC3 -/-hiPSC-CMs indicated a decrease in the contractile force of single hiPSC-CMs as the MYBPC3 dose was reduced 43 . In light of these studies, we decided to solely focus on the MYBPC3 -/-hiPSC-CMs to develop an in vitro disease model, so that we could study how such contractile deficits due to the absence of the MYBPC3 protein would be altered by external mechanical overload and associated gene expression. Importantly, despite the extreme severity of homozygous loss of function of MYBPC3, we only observed pathological phenotypes when hiPSC-CMs were challenged to contract against overload. This suggests that the physical properties of the tissue microenvironment could be used as environmental stress to induce and deteriorate the contractile deficits resulting from the genetic deficiency.
In vitro modelling of the external mechanical load to cardiac tissues has been developed either by passive stretch of cardiac tissues mimicking the increase of preload 44, 45 , or stiffening the flexible cantilevers to cardiac tissues mimicking the increase of afterload 16, 17, 46 . It has been suggested that in vitro systems of engineered cardiac tissues could unmask subtle abnormalities due to genetic deficiencies that were concealed by the compensatory mechanisms in intact animals 47 . Our model facilitated a 3D tissue-like arrangement of hiPSC-CMs, mimicked the increase of afterload and assessed the effects of mechanical overload on cardiac functions. WT cardiac microtissues exhibited enhanced contractile functions in response to the increased afterload. Furthermore, we assessed the contractile deficits of human MYBPC3 -/cardiac microtissues under low and high mechanical load, and found that MYBPC3 -/microtissues only exhibited reduced systolic contraction force on the matrices with stiffer fibres. These data demonstrate that the absence of the MYBPC3 protein impaired physiological adaptation to the mechanical overload, induced contractile deficits and activated pathological signalling.
A previous study on a patient-derived hiPSC line harbouring MYBPC3 mutation indicated myofibril disarray at the single-cell level 48 . Although we observed clear functional deficits in the contractile behaviours of MYBPC3 -/cardiac microtissues, these did not directly correlate with marked changes in the sarcomere structure,
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NaTUre BiOMediCal eNgiNeeriNg indicating that sarcomere disarray may be a consequence, rather than a cause, of contractile dysfunction during the development of MYBPC3 mutation-related cardiomyopathies. This highlights the need for technologies such as genetically encoded sarcomere reporters 25 , which allow researchers to observe in vitro the timing of consecutive sequences for different hallmarks of cardiomyopathy from contractile deficits to structural disarray, or vice versa. Potentially, the combination of biomechanical cues with chemical-induced stress or prolonged culture would lead to structural deficiencies.
To begin understanding the molecular mechanisms underlying the ways in which the environment alters genotype-phenotype relationships, we performed proof-of-concept gene array studies and identified EP300-CBP-GATA4 as a cascade involved in overloadinduced contractile deficits on MYBPC3 -/cardiac microtissues. It has been previously reported that downregulation of C/EBPβ in the heart is associated with overload-induced physiological hypertrophy 49 . Deactivation of the C/EBPβ pathway was associated with upregulation of CITED4, the EP300-CBP interacting transactivator, which promotes the proliferation of cardiomyocytes. Here, we suggest that upregulation of EP300-CBP is also associated with overload-induced contractile deficits, which is consistent with a previous study in which EP300 overexpression led to hypertrophy of cardiomyocytes and the heart in vivo 50 . Pathological stress, such as pressure overload, alters cardiac gene expression and promotes the activation of genes predominantly expressed in the foetal heart. From the MYBPC3 -/cardiac microtissues on 10 µ m matrices, we only found a significant increase of GATA4 expression; the expression of MEF2C and TBX5 also showed an increasing trend, although this was not statistically significant (P < 0.2). In previous studies, heart EP300 chromatin immunoprecipitation sequencing reads were strongly enriched on GATA4 peaks 51, 52 , suggesting that GATA4 directly interacts with EP300-CBP for synergistic gene activation of atrial natriuretic peptide (ANP), BNP and β myosin heavy chain (MYH7) promoters during myocardial hypertrophy 53, 54 . In contrast with indirect means of inducing mechanical stress, such as chronic catecholamine exposure, direct manipulation of the biophysical properties of the in vitro cardiac microenvironment does not introduce additional signalling pathways (for example, G protein-coupled receptor signalling) that complicate mechanistic studies.
MYBPC3 accounts for a significant proportion of familial cardiomyopathies, and is associated with both HCM and DCM. However, the molecular mechanisms linking MYBPC3 mutations to the pathogenesis of cardiomyopathy remain elusive. Our study emphasizes the role of the MYBPC3 protein in regulating cardiac contractile function using a homozygous MYBPC3 knockout isogenic hiPSC line, and demonstrates pronounced DCMlike contractile phenotypes (impaired systolic contraction force, faster decay of calcium dynamics and calcium desensitization) in MYBPC3 -/cardiac microtissues contracting against stiffer fibres. In future studies, our findings relating the importance of overload in modelling cardiomyopathy phenotypes could be leveraged to study the effects of more subtle heterozygous missense or truncated mutations typically found in patients. Importantly, the results obtained from this study with isogenic lines can be used as 'training sets' to calibrate our system and provide 'standards' for subsequent studies on more diverse genetic backgrounds and a greater variety of phenotypes.
Methods
An expanded Methods section is included in the Supplementary Information, with more details on cell handling, motion-tracking analysis, finite element modelling, immunostaining and microscopy, quantitative PCR with reverse transcription, hBNP enzyme-linked immunosorbent assay, flow cytometry, quantitative sarcomere analysis and statistical methods.
Fabrication of filamentous matrices. The filamentous matrices were fabricated by TPP using the photo-curable organic-inorganic hybrid polymer OrmoClear (Micro Resist Technology). Briefly, OrmoClear resin was first spin-coated, prebaked and ultraviolet cured on the glass coverslips. Two glass coverslips with cured OrmoClear thin layers were assembled as one set with 500-μ m-thick spacers and filled with uncured OrmoClear. Individual fibres were fabricated by single laser beam radiation of the uncured OrmoClear through a high-repetitionrate femtosecond laser (pulse duration: ~400 fs, repetition frequency: 1 MHz, wavelength: 1,045 nm; FCPA μ Jewel D-400; IMRA America). The laser beam was frequency-doubled (wavelength: 522 nm) by a lithium triborate (LBO) second harmonic nonlinear crystal (Newlight Photonics) and focused at the interface between the glass coverslip and OrmoClear with a 5× objective (NA = 0.14) (M Plan Apo; Mitutoyo). Fibre diameter was determined by the laser power and exposure duration, which was controlled through a mechanical shutter (Thorlabs). The 5 µ m fibres were fabricated by 3.7 mW power laser radiation for 0.9 s, whereas the 10 µ m fibres were fabricated by 5.2 mW radiation for 2 s. Fibre spacing was controlled by a 3D axis motorized stage with high precision of positioning (ANT95-XY-MP for the x-y axis and ANT95-50-L-Z-RH for the z axis; Aerotech). To fabricate several matrices within one set, we blocked the laser radiation during the movement from the end point of the previous matrix to the starting position of the next matrix. After fibre fabrication, samples were hard-baked for 10 min, developed for 30 min with a mixture of 2-isopropyl alcohol and 4-methyl-2pentanone (1:1; Sigma-Aldrich), rinsed with 2-isopropyl alcohol and deionized water three times and dipped in 70% ethanol for sterilization.
Generation of 3D cardiac microtissues. Three sets of glass devices were placed into one well of a six-well plate and rinsed with Dulbecco's phosphate buffered saline (DPBS; Gibco) three times. Then, diluted Matrigel was adsorbed for at least 1 h. Diluted Matrigel was rinsed off before cell seeding, leaving a thin coating on the individual fibres, instead of Matrigel gel. Cryopreserved hiPSC-CMs were thawed into EB20 media and plated onto a Matrigel-coated six-well plate with RPMI/B27 + C media supplemented with 10 µ M Y-27632. After 4 d of recovery in RPMI/B27 + C media, the cells were singularized by 0.25% trypsin, quenched with EB20 media and seeded into filamentous matrices without ECM proteins or additional Matrigel at a density of 3 million ml −1 RPMI/B27 + C media supplemented with 10 µ M Y-27632. After 4 h, another 4 ml RPMI/B27 + C media supplemented with 10 µ M Y-27632 was added into each well to cover the whole set of filamentous matrices. The media was switched to RPMI/B27 + C media the next day and changed every 2 d. Videos of cardiac microtissue beating were recorded every 5 d for motion-tracking analysis and force measurement.
Fibre characterization. The elastic modulus of the fibre (E f ) was measured by AFM (XE-100; Park Systems) with tipless AFM cantilevers (TL-CONT-SPL and TL-FM-SPL; Nanosensors). The fibre shape was assumed to be a cylinder with a circular cross-section. Hence, the elastic modulus of the fibre was calculated via equation (1): where L and D are the length and diameter of the fibre, respectively, d c is the deflection of the AFM cantilever, and d f is the relative deflection of the fibre. The spring constants (K) of tipless AFM cantilevers were measured using the thermal tuning method 55 and calculated to be 0.0636 N m −1 using AFM software (XEI; Park systems). Finally, the elastic modulus of the fibres with both 5 and 10 µ m diameters was calculated to be 183.9 ± 11.7 MPa.
Force measurement. To calculate the contraction forces of the whole cardiac microtissue, we made three assumptions: (1) the forces were evenly distributed across the tissue cross-section (tissue width multiplied by tissue thickness; W (y axis) × H (z axis)); (2) all of the force vectors were parallel with each other and perpendicular to the fibre axis; and (3) the fibre had a circular cross-section. Based on these assumptions, we calculated the total force (F) generated by the cardiac microtissue by integrating the distributed force (f) across the entire tissue crosssection. To calculate the generated force of the whole cardiac tissue, the individual fibre point force (F′) was calculated based on the beam deflection theory at the position with maximal fibre deflection. Using the series of single-frame images recorded for cardiac tissue beating, we measured the fibre deflection (δ) at specific positions (a) between two consecutive images, so that we could calculate the point force (F′) applied to the fibres based on equation (2) with the elastic modulus (E f ), length (L) and diameter (D) of the fibre:
128 ( ) The distributed force (f) was calculated by dividing the individual fibre point force (F′) by the half-cylinder surface area of the applied force to the fibre. Finally, integrating the distributed force across the entire tissue cross-section, we calculated the total force (F) generated by the cardiac microtissues. The static force was calculated based on the preload fibre defection that was measured with the cardiac microtissue in the resting diastolic state, whereas the contraction force 1 nature research | life sciences reporting summary 
Data exclusions
Describe any data exclusions. No data were excluded from analysis.
Replication
Describe whether the experimental findings were reliably reproduced.
All experiments were reliably reproduced.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Pre-screening of the quality of microtissue formation was performed. Only intact cardiac microtissues grown across the filamentous matrices were selected for further experiments. After the microtissues were selected, samples in all the experiments were randomly allocated when possible.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
For quantitative confocal fluorescent analysis, micrographs generated from cardiac microtissues were encoded for analysis in a user-blinded manner. One co-author recorded all the images, blinded all the information of the images, and sent to the other co-author for fluorescence-intensity analysis.
nature research | life sciences reporting summary
June 2017
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
The motion-tracking software for cardiac tissue contraction analysis is available at https://gladstone.org/46749d811 Our custom sarcomere-analysis software is based on an image-processing algorithm and on 2D Fast Fourier transform and will be available to interested readers on request. Both motion-tracking and sarcomere analysis were performed on MATLAB (R2015a). Finite-element modeling for stress calculation by beam deflection was performed using COMSOL Multiphysics 5.0. General data analysis was performed on GraphPad Prism 7.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
All materials used in this study are readily available from standard commercial sources.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
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June 2017 10. Eukaryotic cell lines a. State the source of each eukaryotic cell line used. The WT hiPSC line was obtained from Prof. Bruce Conklin Lab at Gladstone Institute of Cardiovascular Diseases, and is also available at Coriell Institute NIGMS Human Genetic Cell Repository, GM25256. The MYBPC3-/-hiPSC line is a geneedited hiPSC line with a WTC hiPSC genetic background.
b. Describe the method of cell line authentication used. The hiPSC lines have been well characterized through Stem Cell Biobank, including colony doubling, growth on agar for sterility, PCR for mycoplasma, G-banding karyotype, short tandem repeat (STR) for identify match, immunostainng for surface antigen expression of stem cell markers, and illumine array for pluripotency.
c. Report whether the cell lines were tested for mycoplasma contamination.
The hiPSC lines tested negative for mycoplasma contamination.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide details on animals and/or animal-derived materials used in the study.
No animals were used.
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
The study did not involve human research participants.
